Uploaded August 2026 | Updated November 2026, 4 days ago
People keep saying there’s finally a randomized trial on BPC-157. There is, and it does not show what they think. This segment goes through the one human trial line by line, why an improvement in the treated group is not proof the drug works, and why “it’s natural” and “it’s just a peptide” do not hold up. By the end you will know why these compounds meet the legal definition of a drug.
00:00 The one randomized trial
01:14 Why the numbers cross zero
02:20 The endpoint nobody can look up
02:45 Why "the treated group got better" is not proof
03:21 Wrong condition, wrong route, wrong dose
04:07 The rest of the human record
04:43 "It's natural" does not mean it is not a drug
05:40 Nobody has characterized the parent protein
06:03 Peptide vs protein: the 40-amino-acid line
07:00 Why BPC-157 is suddenly everywhere
08:33 What the word "drug" actually means
Resources:
Barbell Medicine coaching and templates: barbellmedicine.com
Plus podcast subscription: barbellmedicine.com/shop/subscriptions/plus-podcast-subscription
Barbell Medicine Premium: barbellmedicine.com/shop/subscriptions/barbell-medicine-premium
Signal (book pre-order): barbellmedicine.com/shop/learning/signal
References:
1. FDA. PCAC briefing document. Jul 23-24, 2026.
2. FDA. BPC-157 bulk substance review. PCAC 2026. fda.gov/media/193343
3. FDA. TB-500 bulk substance review. PCAC 2026. Media 193349.
4. FDA. KPV, MOTS-c, Semax, Epitalon, Emideltide reviews. 2026.
5. FDA. Questions for the PCAC. Jul 2026.
6. FDA. PCAC roster 2026. Media 193772.
7. FDA. PCAC roster 2022. Media 159040.
8. openFDA. FAERS reports, BPC-157. open.fda.gov
9. 21 CFR 216.23 (2026).
10. FD&C Act 503A; 21 USC 353a.
11. Abigail Alliance v von Eschenbach, 495 F3d 695 (DC Cir 2007).
12. US v Rutherford, 442 US 544 (1979).
13. Right to Try Act of 2017, Pub L 115-176.
14. FDA. Peptide drug products. Draft guidance, 2020.
15. Ruenzi. PL 14736 (BPC 157) in ulcerative colitis. Gastroenterology 2005; abstract only.
16. Staresinic. BPC 157, transected rat quadriceps. J Orthop Res 2006;24:1109.
17. Gwyer. BPC 157 and soft tissue healing. Cell Tissue Res 2019;377:153.
18. Sikiric. BPC 157, hemorrhage/thrombosis. Pharmaceuticals 2026;19:463.
19. Stavchansky. Glyprolines and gene expression, Semax. Genes 2022;13:2380.
20. Mendias. Approved and unapproved peptides. Sports Med 2026.
21. Moseley. Arthroscopic surgery for knee OA. NEJM 2002;347:81.
22. Cobb. Internal mammary ligation, double-blind. NEJM 1959;260:1115.
23. Dimond. IMA ligation vs sham for angina. Am J Cardiol 1960;5:483.
24. Alfredson. Eccentric calf training, Achilles tendinosis. AJSM 1998;26:360.
25. Kongsgaard. Steroid vs exercise, patellar tendinopathy. Scand J Med Sci Sports 2009;19:790.
26. Langberg. Peritendinous metabolism during exercise. J Physiol 1999;515:919.
27. Coombes. Steroid vs physiotherapy, tennis elbow. JAMA 2013;309:461.
28. Kearney. PRP vs sham, Achilles tendinopathy. JAMA 2021;326:137.
29. Pavlova. Exercise dose in tendinopathy, meta-analysis. BJSM 2023;57:1327.
30. Weintraub. Fen-phen vs placebo. Clin Pharmacol Ther 1992;51:586.
31. Connolly. Valvular heart disease with fen-phen. NEJM 1997;337:581.
32. CDC. Valvulopathy with fenfluramine. MMWR 1997;46:1061.
33. Bombardier. VIGOR: rofecoxib vs naproxen. NEJM 2000;343:1520.
34. Graham. MI and sudden death, COX-2 inhibitors. Lancet 2005;365:475.
35. Smith. Fungal infections, contaminated methylprednisolone. NEJM 2013;369:1598.
36. Adunsky. MK-0677 after hip fracture. Arch Gerontol Geriatr 2011;53:183. Halted early, CHF signal.
37. Nass. Oral ghrelin mimetic in older adults. Ann Intern Med 2008;149:601.
38. Van Wagoner. Composition of SARMs sold online. JAMA 2017;318:2004.
39. ECRI/ISMP. Unapproved peptide products. Apr 2026.
40. CSPI. Are injectable peptides safe? cspinet.org
41. WADA. 2026 Prohibited List. wada-ama.org
42. USADA. BPC-157: a prohibited peptide. usada.org
43. Time. FDA panel backs compounding peptides. Jul 2026.
44. RAPS. Committee backs controversial peptides. 2026.
45. STAT. Panel okays peptides for compounding. Jul 2026.
46. NBC News. Panel eases peptide limits over FDA objections. 2026.
47. AP. Financial ties among FDA peptide panel members. 2026.
48. Leerink. PCAC vote and telehealth compounding market. 2026.
49. Examine.com. BPC-157 research breakdown. examine.com/supplements/bpc-157
50. Jarry. BPC: no proof required. McGill OSS. mcgill.ca/oss
People keep saying there’s finally a randomized trial on BPC-157. There is, and it does not show what they think. This segment goes through the one human trial line by line, why an improvement in the treated group is not proof the drug works, and why “it’s natural” and “it’s just a peptide” do not hold up. By the end you will know why these compounds meet the legal definition of a drug.
00:00 The one randomized trial
01:14 Why the numbers cross zero
02:20 The endpoint nobody can look up
02:45 Why "the treated group got better" is not proof
03:21 Wrong condition, wrong route, wrong dose
04:07 The rest of the human record
04:43 "It's natural" does not mean it is not a drug
05:40 Nobody has characterized the parent protein
06:03 Peptide vs protein: the 40-amino-acid line
07:00 Why BPC-157 is suddenly everywhere
08:33 What the word "drug" actually means
Resources:
Barbell Medicine coaching and templates: barbellmedicine.com
Plus podcast subscription: barbellmedicine.com/shop/subscriptions/plus-podcast-subscription
Barbell Medicine Premium: barbellmedicine.com/shop/subscriptions/barbell-medicine-premium
Signal (book pre-order): barbellmedicine.com/shop/learning/signal
References:
1. FDA. PCAC briefing document. Jul 23-24, 2026.
2. FDA. BPC-157 bulk substance review. PCAC 2026. fda.gov/media/193343
3. FDA. TB-500 bulk substance review. PCAC 2026. Media 193349.
4. FDA. KPV, MOTS-c, Semax, Epitalon, Emideltide reviews. 2026.
5. FDA. Questions for the PCAC. Jul 2026.
6. FDA. PCAC roster 2026. Media 193772.
7. FDA. PCAC roster 2022. Media 159040.
8. openFDA. FAERS reports, BPC-157. open.fda.gov
9. 21 CFR 216.23 (2026).
10. FD&C Act 503A; 21 USC 353a.
11. Abigail Alliance v von Eschenbach, 495 F3d 695 (DC Cir 2007).
12. US v Rutherford, 442 US 544 (1979).
13. Right to Try Act of 2017, Pub L 115-176.
14. FDA. Peptide drug products. Draft guidance, 2020.
15. Ruenzi. PL 14736 (BPC 157) in ulcerative colitis. Gastroenterology 2005; abstract only.
16. Staresinic. BPC 157, transected rat quadriceps. J Orthop Res 2006;24:1109.
17. Gwyer. BPC 157 and soft tissue healing. Cell Tissue Res 2019;377:153.
18. Sikiric. BPC 157, hemorrhage/thrombosis. Pharmaceuticals 2026;19:463.
19. Stavchansky. Glyprolines and gene expression, Semax. Genes 2022;13:2380.
20. Mendias. Approved and unapproved peptides. Sports Med 2026.
21. Moseley. Arthroscopic surgery for knee OA. NEJM 2002;347:81.
22. Cobb. Internal mammary ligation, double-blind. NEJM 1959;260:1115.
23. Dimond. IMA ligation vs sham for angina. Am J Cardiol 1960;5:483.
24. Alfredson. Eccentric calf training, Achilles tendinosis. AJSM 1998;26:360.
25. Kongsgaard. Steroid vs exercise, patellar tendinopathy. Scand J Med Sci Sports 2009;19:790.
26. Langberg. Peritendinous metabolism during exercise. J Physiol 1999;515:919.
27. Coombes. Steroid vs physiotherapy, tennis elbow. JAMA 2013;309:461.
28. Kearney. PRP vs sham, Achilles tendinopathy. JAMA 2021;326:137.
29. Pavlova. Exercise dose in tendinopathy, meta-analysis. BJSM 2023;57:1327.
30. Weintraub. Fen-phen vs placebo. Clin Pharmacol Ther 1992;51:586.
31. Connolly. Valvular heart disease with fen-phen. NEJM 1997;337:581.
32. CDC. Valvulopathy with fenfluramine. MMWR 1997;46:1061.
33. Bombardier. VIGOR: rofecoxib vs naproxen. NEJM 2000;343:1520.
34. Graham. MI and sudden death, COX-2 inhibitors. Lancet 2005;365:475.
35. Smith. Fungal infections, contaminated methylprednisolone. NEJM 2013;369:1598.
36. Adunsky. MK-0677 after hip fracture. Arch Gerontol Geriatr 2011;53:183. Halted early, CHF signal.
37. Nass. Oral ghrelin mimetic in older adults. Ann Intern Med 2008;149:601.
38. Van Wagoner. Composition of SARMs sold online. JAMA 2017;318:2004.
39. ECRI/ISMP. Unapproved peptide products. Apr 2026.
40. CSPI. Are injectable peptides safe? cspinet.org
41. WADA. 2026 Prohibited List. wada-ama.org
42. USADA. BPC-157: a prohibited peptide. usada.org
43. Time. FDA panel backs compounding peptides. Jul 2026.
44. RAPS. Committee backs controversial peptides. 2026.
45. STAT. Panel okays peptides for compounding. Jul 2026.
46. NBC News. Panel eases peptide limits over FDA objections. 2026.
47. AP. Financial ties among FDA peptide panel members. 2026.
48. Leerink. PCAC vote and telehealth compounding market. 2026.
49. Examine.com. BPC-157 research breakdown. examine.com/supplements/bpc-157
50. Jarry. BPC: no proof required. McGill OSS. mcgill.ca/oss





![Is Creatine Causing Your Shin Pain? +Splitting Training, Endometriosis for Lifters | Direct Line May
This is a free preview of the May 2026 Direct Line, our monthly AMA for Barbell Medicine Plus. Dr. Jordan Feigenbaum and Dr. Austin Baraki walk through three reader questions: whether creatine is actually causing exertional shin pain in a mid-30s woman, whether splitting your resistance training across the day affects strength and hypertrophy, and a primer on training and nutrition for women with endometriosis.
The full unabridged Direct Line covers 10 more questions, including where the GLP-1 strength trials actually are, why DEXA is misleading on muscle mass loss, how we built the Vital 5 weightings, the salt sermon for strongman, running shoes for casual runners, and a fresh reading list. Full episode on BBM Plus at the link below.
Submit questions for next month’s Direct Line on your BBM Plus dashboard.
Chapters:
00:00 Welcome to Direct Line · May 2026
00:10 Question 1 · Creatine and shin pain
12:18 Question 2 · Splitting your workout across the day
19:52 Question 3 · Endometriosis for the lifter
~32:00 Full episode continues on BBM Plus
Resources:
Subscribe to BBM Plus for the full unabridged Direct Line: https://barbellmedicine.supercast.com/
Barbell Medicine coaching and templates: https://www.barbellmedicine.com/
Signal book pre-order: https://www.barbellmedicine.com/shop/learning/signal/
Waterman B.R. et al. 2013. Risk factors for chronic exertional compartment syndrome in a physically active military population. Am J Sports Med 41(11):2545-2552.
https://pubmed.ncbi.nlm.nih.gov/24036570/
Powers M.E. et al. 2003. Creatine supplementation increases total body water without altering fluid distribution. J Athl Train 38(1):44-50.
https://pubmed.ncbi.nlm.nih.gov/12937471/
Antonio J. et al. 2021. Common questions and misconceptions about creatine supplementation (ISSN position). J Int Soc Sports Nutr 18(1):13.
https://pubmed.ncbi.nlm.nih.gov/33557850/
Bruneau A. et al. 2025. Creatine supplementation associated with chronic exertional compartment syndrome: case report. [TO ADD: PMID once indexed]
Schoenfeld B.J. et al. 2016. Effects of resistance training frequency on measures of muscle hypertrophy: a systematic review and meta-analysis. Sports Med 46(11):1689-1697.
https://pubmed.ncbi.nlm.nih.gov/27102172/
Schoenfeld B.J. et al. 2019. How many times per week should a muscle be trained to maximize hypertrophy? J Sports Sci 37(11):1286-1295.
https://pubmed.ncbi.nlm.nih.gov/30558493/
ESHRE Endometriosis Guideline Development Group. 2022. ESHRE guideline: endometriosis. Hum Reprod Open 2022(2):hoac009.
https://pubmed.ncbi.nlm.nih.gov/35350465/
McNulty K.L. et al. 2020. The effects of menstrual cycle phase on exercise performance in eumenorrheic women: systematic review and meta-analysis. Sports Med 50(10):1813-1827.
https://pubmed.ncbi.nlm.nih.gov/32661839/ Is Creatine Causing Your Shin Pain? +Splitting Training, Endometriosis for Lifters | Direct Line May](https://i.ytimg.com/vi/7Ao3FI51T8I/mqdefault.jpg)




